Jubilant Life Sciences’ US based subsidiary - Jubilant Cadista, has recalled its drug Pantoprazole Sodium (delayed release) from the US market. The drug was manufactured at the company’s India facility at Roorkee and was pulled out for possible deviations from prescribed good manufacturing practices (cGMP). The US Food and Drug Administration (USFDA) has mentioned the reason of recall as cGMP deviations; oral products were not manufactured in accordance with good manufacturing practices.
The recall has been classified as class II, which means use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Jubilant’s nationwide pull-out of affected lots in US is a voluntary recall, initiated by the firm.
The drug Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: